Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Ulrik Morch"'
Autor:
M. Andersen, Niels Henrik Søe, Ulrik Morch, Bente Danneskiold-Samsøe, Søren Torp-Pedersen, Mikael Boesen, Else Marie Bartels, Kalle Söderström, Pieter Spee, Karen Ellegaard, Henning Bliddal, Lars Karlsson
Publikováno v:
PLoS ONE, Vol 13, Iss 5, p e0197001 (2018)
PLoS ONE
Andersen, M, Boesen, M, Ellegaard, K, Söderström, K, Søe, N H, Spee, P, Mørch, U G W, Torp-Pedersen, S, Bartels, E M, Danneskiold-Samsøe, B, Karlsson, L & Bliddal, H 2018, ' Association between IL-6 production in synovial explants from rheumatoid arthritis patients and clinical and imaging response to biologic treatment : A pilot study ', PLoS ONE, vol. 13, no. 5, e0197001 . https://doi.org/10.1371/journal.pone.0197001
PLoS ONE
Andersen, M, Boesen, M, Ellegaard, K, Söderström, K, Søe, N H, Spee, P, Mørch, U G W, Torp-Pedersen, S, Bartels, E M, Danneskiold-Samsøe, B, Karlsson, L & Bliddal, H 2018, ' Association between IL-6 production in synovial explants from rheumatoid arthritis patients and clinical and imaging response to biologic treatment : A pilot study ', PLoS ONE, vol. 13, no. 5, e0197001 . https://doi.org/10.1371/journal.pone.0197001
INTRODUCTION: The need for biomarkers which can predict disease course and treatment response in rheumatoid arthritis (RA) is evident. We explored whether clinical and imaging responses to biologic disease modifying anti-rheumatic drug treatment (bDM
Autor:
Ulrik Morch, M. Andersen, Karen Ellegaard, Robin Christensen, Pieter Spee, Niels Henrik Søe, Henning Bliddal, Lars Karlsson, Søren Torp-Pedersen, N. Vendel, Mikael Boesen, Else Marie Bartels, Bente Danneskiold-Samsøe, Kalle Söderström
Publikováno v:
Andersen, M, Boesen, M, Ellegaard, K, Christensen, R, Söderström, K, Søe, N, Spee, P, Mørch, U G, Torp-Pedersen, S, Bartels, E M, Danneskiold-Samsøe, B, Vendel, N, Karlsson, L & Bliddal, H 2014, ' Synovial explant inflammatory mediator production corresponds to rheumatoid arthritis imaging hallmarks : a cross-sectional study ', Arthritis Research & Therapy, vol. 16, R107 . https://doi.org/10.1186/ar4557
Andersen, M, Boesen, M, Ellegaard, K, Christensen, R, Söderström, K, Søe, N, Spee, P, Mørch, U G, Torp-Pedersen, S, Bartels, E M, Danneskiold-Samsøe, B, Vendel, N, Karlsson, L & Bliddal, H 2014, ' Synovial explant inflammatory mediator production corresponds to rheumatoid arthritis imaging hallmarks : a cross-sectional study ', Arthritis Research & Therapy
, vol. 16, no. 3, R107 . https://doi.org/10.1186/ar4557
Arthritis Research & Therapy
Andersen, M, Boesen, M, Ellegaard, K, Christensen, R, Söderström, K, Søe, N, Spee, P, Mørch, U G, Torp-Pedersen, S, Bartels, E M, Danneskiold-Samsøe, B, Vendel, N, Karlsson, L & Bliddal, H 2014, ' Synovial explant inflammatory mediator production corresponds to rheumatoid arthritis imaging hallmarks : a cross-sectional study ', Arthritis Research & Therapy
, vol. 16, no. 3, R107 . https://doi.org/10.1186/ar4557
Arthritis Research & Therapy
Introduction: Despite the widespread use of magnetic resonance imaging (MRI) and Doppler ultrasound for the detection of rheumatoid arthritis (RA) disease activity, little is known regarding the association of imaging-detected activity and synovial p
Autor:
Else Marie Bartels, Bente Danneskiold-Samsøe, Søren Torp-Pedersen, Morten Ilum Boesen, M. Andersen, Karen Ellegaard, Niels Henrik Søe, Lars Karlsson, Henning Bliddal, Ulrik Morch, Kalle Söderström, Pieter Spee
Publikováno v:
Annals of the Rheumatic Diseases. 74:70.1-70
Background It remains to be clarified whether disease changes detected by color Doppler ultrasound (CDUS) and magnetic resonance imaging (MRI) during biological treatment reflect alterations of synovial pathology in rheumatoid arthritis (RA). Objecti
Autor:
Bente Danneskiold-Samsøe, M. Andersen, René dePont Christensen, Karen Ellegaard, N. Vendel, Henning Bliddal, Morten Ilum Boesen, Niels Henrik Søe, Lars Karlsson, Pieter Spee, Ulrik Morch, Søren Torp-Pedersen, Kalle Söderström, Else Marie Bartels
Publikováno v:
Annals of the Rheumatic Diseases. 73:388.2-389
Background Remission is only achieved in part of rheumatoid arthritis (RA) patients treated with synthetic disease modifying anti-rheumatic drugs, sDMARDs. The increasing number of available biologic DMARDs (bDMARDs) challenges treatment decision mak